First Time Loading...

Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 301.08 USD 0.13% Market Closed
Updated: Jun 13, 2024
Have any thoughts about
Amgen Inc?
Write Note

Intrinsic Value

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. [ Read More ]

The intrinsic value of one AMGN stock under the Base Case scenario is 241.11 USD. Compared to the current market price of 301.08 USD, Amgen Inc is Overvalued by 20%.

Key Points:
AMGN Intrinsic Value
Base Case
241.11 USD
Overvaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amgen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AMGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amgen Inc

Current Assets 28B
Cash & Short-Term Investments 9.7B
Receivables 6.8B
Other Current Assets 11.5B
Non-Current Assets 65B
PP&E 6B
Intangibles 49.9B
Other Non-Current Assets 9B
Current Liabilities 19.7B
Accounts Payable 1.6B
Accrued Liabilities 14.1B
Other Current Liabilities 4B
Non-Current Liabilities 68.2B
Long-Term Debt 60.1B
Other Non-Current Liabilities 8.2B
Efficiency

Earnings Waterfall
Amgen Inc

Revenue
29.5B USD
Cost of Revenue
-9.9B USD
Gross Profit
19.6B USD
Operating Expenses
-12.5B USD
Operating Income
7.1B USD
Other Expenses
-3.3B USD
Net Income
3.8B USD

Free Cash Flow Analysis
Amgen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AMGN Profitability Score
Profitability Due Diligence

Amgen Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
73/100
Profitability
Score

Amgen Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

AMGN Solvency Score
Solvency Due Diligence

Amgen Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Low Altman Z-Score
34/100
Solvency
Score

Amgen Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 324.92 USD with a low forecast of 171.7 USD and a high forecast of 399 USD.

Lowest
Price Target
171.7 USD
43% Downside
Average
Price Target
324.92 USD
8% Upside
Highest
Price Target
399 USD
33% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AMGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AMGN Price
Amgen Inc

1M 1M
-2%
6M 6M
+7%
1Y 1Y
+36%
3Y 3Y
+33%
5Y 5Y
+92%
10Y 10Y
+233%
Annual Price Range
301.08
52w Low
218.65
52w High
324.56
Price Metrics
Average Annual Return 14.24%
Standard Deviation of Annual Returns 18.23%
Max Drawdown -19%
Shares Statistics
Market Capitalization 161.5B USD
Shares Outstanding 536 435 008
Percentage of Shares Shorted 1.91%

AMGN Return Decomposition
Main factors of price return

What is price return decomposition?

AMGN News

Other Videos

Last Important Events
Amgen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Amgen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Amgen Inc Logo
Amgen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

161.5B USD

Dividend Yield

2.99%

Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

Contact

CALIFORNIA
Thousand Oaks
1 Amgen Center Dr
+18054471000.0
http://www.amgen.com/

IPO

1983-06-17

Employees

24 200

Officers

Chairman, CEO & President
Mr. Robert A. Bradway
Executive VP & CFO
Mr. Peter H. Griffith
Executive Vice President of Operations
Mr. Esteban Santos
Executive VP & Chief Technology Officer
Dr. David M. Reese M.D.
Executive Vice President of Global Commercial Operations
Mr. Murdo Gordon
Chief Accounting Officer & VP of Finance
Mr. Matthew C. Busch
Show More
Senior VP & Chief Information Officer
Mr. Mike Zahigian
Executive VP of Research and Development & Chief Scientific Officer
Dr. James E. Bradner M.D.
Vice President of Investor Relations
Justin G. Claeys
Executive VP, General Counsel & Secretary
Mr. Jonathan P. Graham
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMGN stock?

The intrinsic value of one AMGN stock under the Base Case scenario is 241.11 USD.

Is AMGN stock undervalued or overvalued?

Compared to the current market price of 301.08 USD, Amgen Inc is Overvalued by 20%.